[go: up one dir, main page]

LT3300B - Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor - Google Patents

Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor Download PDF

Info

Publication number
LT3300B
LT3300B LTIP1514A LTIP1514A LT3300B LT 3300 B LT3300 B LT 3300B LT IP1514 A LTIP1514 A LT IP1514A LT IP1514 A LTIP1514 A LT IP1514A LT 3300 B LT3300 B LT 3300B
Authority
LT
Lithuania
Prior art keywords
cholesterol
inhibitor
lower alkyl
phenyl
heteroaryl
Prior art date
Application number
LTIP1514A
Other languages
English (en)
Lithuanian (lt)
Inventor
Harry R Davis
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of LTIP1514A publication Critical patent/LTIP1514A/xx
Publication of LT3300B publication Critical patent/LT3300B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
LTIP1514A 1992-12-23 1993-12-03 Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor LT3300B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99548892A 1992-12-23 1992-12-23

Publications (2)

Publication Number Publication Date
LTIP1514A LTIP1514A (en) 1994-10-25
LT3300B true LT3300B (en) 1995-06-26

Family

ID=25541876

Family Applications (1)

Application Number Title Priority Date Filing Date
LTIP1514A LT3300B (en) 1992-12-23 1993-12-03 Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor

Country Status (32)

Country Link
US (1) US5661145A (zh)
EP (1) EP0675714B1 (zh)
JP (1) JP3992728B2 (zh)
KR (1) KR100306936B1 (zh)
CN (1) CN1090479C (zh)
AT (1) ATE175872T1 (zh)
AU (1) AU680864B2 (zh)
CA (1) CA2152351C (zh)
CZ (1) CZ287125B6 (zh)
DE (1) DE69323213T2 (zh)
DK (1) DK0675714T3 (zh)
EE (1) EE03383B1 (zh)
ES (1) ES2128552T3 (zh)
FI (1) FI952916A (zh)
GR (1) GR3029405T3 (zh)
HR (1) HRP931515B1 (zh)
HU (1) HU221724B1 (zh)
IL (1) IL108112A (zh)
LT (1) LT3300B (zh)
LV (1) LV10919B (zh)
MX (1) MX9308053A (zh)
MY (1) MY109538A (zh)
NO (1) NO311325B1 (zh)
NZ (1) NZ259790A (zh)
PL (1) PL174128B1 (zh)
SG (1) SG45147A1 (zh)
SI (1) SI9300677A (zh)
SK (1) SK281173B6 (zh)
TW (1) TW319698B (zh)
WO (1) WO1994014433A1 (zh)
YU (1) YU49060B (zh)
ZA (1) ZA939552B (zh)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
WO1996009827A2 (en) * 1994-09-20 1996-04-04 Pfizer Inc. Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor
US5624920A (en) * 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
EA000514B1 (ru) 1995-11-02 1999-10-28 Варнер-Ламберт Компани Способ нормализации липопротеидного профиля плазмы крови у млекопитающего и фармацевтическая композиция для его осуществления
US20030153541A1 (en) * 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
AR023463A1 (es) * 1999-04-16 2002-09-04 Schering Corp Uso de compuestos de azetidinona
JP4945876B2 (ja) * 2000-04-05 2012-06-06 東レ株式会社 ハイモビリティーグループタンパクの吸着材および体液浄化カラム
US6979462B1 (en) * 2000-10-03 2005-12-27 Mutual Pharmaceutical Co., Inc. Stabilization of solid drug formulations
US6584357B1 (en) * 2000-10-17 2003-06-24 Sony Corporation Method and system for forming an acoustic signal from neural timing difference data
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
CN101297969B (zh) * 2001-01-26 2011-03-09 先灵公司 过氧化物酶体增殖物激活受体(ppar)活化剂和甾醇吸收抑制剂的组合药
IL157552A0 (en) 2001-03-28 2004-03-28 Schering Corp Enantioselective synthesis of azetidinone intermediate compounds
MXPA04002572A (es) * 2001-09-21 2004-05-31 Schering Corp Metodos para el tratamiento o prevencion de inflamacion vascular usando inhibidores de absorcion de esterol.
WO2003026643A2 (en) * 2001-09-21 2003-04-03 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US6984645B2 (en) 2001-11-16 2006-01-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
US20030204096A1 (en) * 2002-03-25 2003-10-30 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US7135556B2 (en) * 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
ES2350977T3 (es) 2002-11-05 2011-01-28 Glaxo Group Limited Agentes antibacterianos.
MXPA05009503A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
DE602004018617D1 (de) 2003-03-07 2009-02-05 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
EP1606287B1 (en) * 2003-03-07 2013-10-02 Merck Sharp & Dohme Corp. Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
EP1810971B1 (en) * 2003-03-07 2013-12-25 Merck Sharp & Dohme Corp. Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
JP2005015434A (ja) * 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
US20060089374A1 (en) * 2003-07-17 2006-04-27 Glenn Cornett Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease
US20050113314A1 (en) * 2003-08-29 2005-05-26 Fong Benson M. Cicletanine in combination with oral antidiabetic and/or blood lipid-lowering agents as a combination therapy for diabetes and metabolic syndrome
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
EP1918000A2 (en) 2003-11-05 2008-05-07 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
JP2007516287A (ja) * 2003-12-23 2007-06-21 メルク　エンド　カムパニー　インコーポレーテッド 抗高コレステロール血症化合物
CA2550215A1 (en) 2003-12-23 2005-07-07 Astrazeneca Ab Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
GB0329778D0 (en) * 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
CA2553769C (en) * 2004-01-16 2011-01-04 Merck & Co., Inc. Npc1l1 (npc3) and methods of identifying ligands thereof
CN101006074B (zh) * 2004-07-01 2012-02-15 欧科生医股份有限公司 作为nk1拮抗剂的哌啶衍生物
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
US20060046996A1 (en) 2004-08-31 2006-03-02 Kowa Co., Ltd. Method for treating hyperlipidemia
US20060154959A1 (en) * 2005-01-13 2006-07-13 Navitas Pharma Combination therapies of cicletanine and carvedilol
JP2008514718A (ja) * 2004-09-29 2008-05-08 シェーリング コーポレイション 置換アゼチドノンおよびｃｂ１アンタゴニストの組み合わせ
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
WO2006076598A2 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076568A2 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Thiazolopyridines as cannabinoid receptor modulators
WO2006076597A1 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US20080096915A1 (en) * 2005-01-13 2008-04-24 Greenberg Traurig LLP Compositions for the treatment of metabolic disorders
US20070141174A1 (en) * 2005-01-13 2007-06-21 Navitas Pharma, Inc. Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension
US20060160850A1 (en) 2005-01-18 2006-07-20 Chongqing Sun Bicyclic heterocycles as cannabinoid receptor modulators
DE602006004964D1 (de) 2005-02-10 2009-03-12 Bristol Myers Squibb Co Dihydrochinazolinone als 5ht-modulatoren
US7629342B2 (en) 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US7317012B2 (en) 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
US7572808B2 (en) 2005-06-17 2009-08-11 Bristol-Myers Squibb Company Triazolopyridine cannabinoid receptor 1 antagonists
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
UY29607A1 (es) * 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
JP2008546784A (ja) * 2005-06-20 2008-12-25 シェーリング コーポレイション ヒスタミンｈ３アンタゴニストとして有用なピペリジン誘導体
AR054482A1 (es) * 2005-06-22 2007-06-27 Astrazeneca Ab Derivados de azetidinona para el tratamiento de hiperlipidemias
MY148538A (en) * 2005-06-22 2013-04-30 Astrazeneca Ab Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
AR057383A1 (es) * 2005-06-22 2007-12-05 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AR057380A1 (es) * 2005-06-22 2007-11-28 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
US7795436B2 (en) 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
AR056155A1 (es) 2005-10-26 2007-09-19 Bristol Myers Squibb Co Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
US20070105817A1 (en) * 2005-11-09 2007-05-10 Jim Page Use of cicletanine and other furopyridines for treatment of systolic-predominant hypertension, isolated systolic hypertension, elevated pulse pressure, and general hypertension
WO2007075702A2 (en) * 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
WO2007100807A2 (en) 2006-02-24 2007-09-07 Schering Corporation Npc1l1 orthologues
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
US20070275052A1 (en) * 2006-05-24 2007-11-29 Glenmark Pharmaceuticals Limited Pharmaceutical compositions containing sterol inhibitors
US20080103122A1 (en) * 2006-09-05 2008-05-01 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
US20080312241A1 (en) * 2007-01-03 2008-12-18 Gilead Sciences, Inc. Cicletanine and PKC inhibitors in the treatment of pulmonary and cardiac disorders
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
WO2010021681A2 (en) * 2008-08-18 2010-02-25 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
EP2411005A1 (en) 2009-03-27 2012-02-01 Bristol-Myers Squibb Company Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors
EP2892897A1 (en) 2012-09-05 2015-07-15 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
EP2892896B1 (en) 2012-09-05 2016-06-29 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists
KR20210034039A (ko) 2018-07-19 2021-03-29 아스트라제네카 아베 다파글리플로진을 사용하는 HFpEF의 치료 방법 및 이를 포함하는 조성물
IL308122A (en) 2021-06-16 2023-12-01 Celgene Corp Azetidinyl compounds consisting of a carboxylic acid group for the treatment of neurodegenerative diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993002048A1 (en) 1991-07-23 1993-02-04 Schering Corporation Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
US9205972B2 (en) 2012-01-26 2015-12-08 Intralot S.A.—Integrated Lottery Systems and Services Methods and systems for dispensing

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US4983597A (en) * 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5120729A (en) * 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
US5085473A (en) * 1990-10-09 1992-02-04 Yuhe Yang Air actuated car curtain device

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993002048A1 (en) 1991-07-23 1993-02-04 Schering Corporation Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
US9205972B2 (en) 2012-01-26 2015-12-08 Intralot S.A.—Integrated Lottery Systems and Services Methods and systems for dispensing

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHARLES C. ALLAIN, LUCY S. POON, CICELY S. G.: "Enzymatic Determination of Total Serum Cholesterol", CLINICAL CHEMISTRY, 1974, pages 470 - 475
SCHNITZER-POLOKOFF ET AL: "Effects of acyl-CoA: cholesterol O-acyltransferase inhibition on cholesterol absorption and plasma lipoprotein composition in hamster", COMP. BIOCHEM. PHYSIOL., 1991, pages 665 - 670, XP025223397, DOI: doi:10.1016/0300-9629(91)90147-5

Also Published As

Publication number Publication date
IL108112A0 (en) 1994-04-12
CN1095591A (zh) 1994-11-30
AU5872094A (en) 1994-07-19
CN1090479C (zh) 2002-09-11
CZ287125B6 (en) 2000-09-13
CZ164395A3 (en) 1996-03-13
SK78395A3 (en) 1996-05-08
SK281173B6 (sk) 2000-12-11
WO1994014433A1 (en) 1994-07-07
PL309636A1 (en) 1995-10-30
HU9501854D0 (en) 1995-08-28
CA2152351C (en) 2009-09-22
JP3992728B2 (ja) 2007-10-17
SG45147A1 (en) 1998-01-16
DK0675714T3 (da) 1999-09-13
HRP931515B1 (en) 2000-02-29
NZ259790A (en) 1997-02-24
LV10919B (en) 1996-04-20
EE03383B1 (et) 2001-04-16
EP0675714B1 (en) 1999-01-20
EP0675714A1 (en) 1995-10-11
HRP931515A2 (en) 1996-12-31
ZA939552B (en) 1994-10-12
YU80293A (sh) 1997-12-05
US5661145A (en) 1997-08-26
LTIP1514A (en) 1994-10-25
NO952529L (no) 1995-06-23
CA2152351A1 (en) 1994-07-07
FI952916A0 (fi) 1995-06-14
NO952529D0 (no) 1995-06-23
DE69323213D1 (de) 1999-03-04
KR100306936B1 (ko) 2001-11-30
MX9308053A (es) 1994-06-30
ATE175872T1 (de) 1999-02-15
YU49060B (sh) 2003-08-29
NO311325B1 (no) 2001-11-19
PL174128B1 (pl) 1998-06-30
HUT72081A (en) 1996-03-28
GR3029405T3 (en) 1999-05-28
JPH08505141A (ja) 1996-06-04
IL108112A (en) 1999-11-30
AU680864B2 (en) 1997-08-14
EE9400341A (et) 1996-04-15
ES2128552T3 (es) 1999-05-16
MY109538A (en) 1997-02-28
DE69323213T2 (de) 1999-07-08
HU221724B1 (hu) 2002-12-28
FI952916A (fi) 1995-06-14
TW319698B (zh) 1997-11-11
LV10919A (lv) 1995-12-20
SI9300677A (en) 1994-09-30

Similar Documents

Publication Publication Date Title
LT3300B (en) Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
US5157025A (en) Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
US8853229B2 (en) Composition containing statins and omega-3 fatty acids
EP1353696B1 (en) Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
Kleinveld et al. Comparative study on the effect of low-dose vitamin E and probucol on the susceptibility of LDL to oxidation and the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits.
JP2004532186A (ja) シトステロール血症の処置のための置換アゼチジノン化合物の使用
JP2016135762A (ja) 高脂血症および高コレステロール血症に関連する障害または疾患を、副作用を最小限にしつつ処置するための方法
JP3873097B2 (ja) 抗肥満剤及び脂質代謝改善剤
Zimetbaum et al. Probucol: pharmacology and clinical application
JP3858055B2 (ja) 抗肥満剤及び脂質代謝改善剤
JP2001527551A (ja) Ｍｔｐインヒビターと脂溶性ビタミンの組合せおよび該組合せを用いる血清脂質レベルの降下法
HOLMES Drugs affecting lipid synthesis
WO1998001119A2 (en) Pharmaceutical compositions comprising simvastatin
NZ299704A (en) Use of a beta-lactam cholesterol absorption inhibitor and a cholesterol biosynthesis inhibitor (eg lovastatin) in preparation of pharmaceutical compositions for treatment of plasma cholesterol levels
US20020086855A1 (en) Medicament for treating obesity and improving lipid metabolism
JP2006225395A (ja) 抗肥満剤及び脂質代謝改善剤
Lorimer et al. Atherosclerosis and Hyperlipoproteinaemia
KR20030023698A (ko) 카르복시알킬에테르를 사용하여 섭식 장애를 치료하는 방법

Legal Events

Date Code Title Description
TH9A Changes in patent title/claims
MM9A Lapsed patents

Effective date: 20111203